155 related articles for article (PubMed ID: 36173344)
1. A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease.
Ge T; Yang Y; Zhao Y
Perfusion; 2023 Nov; 38(8):1697-1704. PubMed ID: 36173344
[TBL] [Abstract][Full Text] [Related]
2. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
Du H; Li X; Zhao W; Jiang N
J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898
[TBL] [Abstract][Full Text] [Related]
3. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
4. Study on the application effect of bisoprolol combined with sacubitril valsartan sodium tablets in the cardiac rehabilitation of patients with acute myocardial infarction combined with left heart failure after percutaneous coronary intervention (PCI).
Chen C; Wu X; Li Y; Peng Y
Ann Palliat Med; 2021 May; 10(5):5455-5461. PubMed ID: 34044572
[TBL] [Abstract][Full Text] [Related]
5. Effect of sacubitril-valsartan on left ventricular remodeling and NT-proBNP in patients with heart failure complicated with hypertension and reduced ejection fraction.
Xie B; Gao Q; Wang Y; Du J; He Y
Am J Transl Res; 2024; 16(5):1935-1944. PubMed ID: 38883372
[TBL] [Abstract][Full Text] [Related]
6. The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction.
Chen F; Tian G; Bai X; Li J; Yuan Z
Ann Palliat Med; 2021 Aug; 10(8):8684-8691. PubMed ID: 34488357
[TBL] [Abstract][Full Text] [Related]
7. Effect of sacubitril valsartan on cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction.
Li BH; Fang KF; Lin PH; Zhang YH; Huang YX; Jie H
Clin Hemorheol Microcirc; 2021; 77(4):425-433. PubMed ID: 33386797
[TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction.
Jiang J; Gao J; Zhang X; Li Y; Dang H; Liu Y; Chen W
Front Cardiovasc Med; 2023; 10():1097066. PubMed ID: 37034349
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of enhanced external counter pulsation plus sacubitril/valsartan in the treatment of patients with chronic heart failure and the effect on ankle-arm index and cardiac function.
Huang XL; Wang XJ; Chen BT; Chen YN
Eur Rev Med Pharmacol Sci; 2023 Apr; 27(8):3300-3312. PubMed ID: 37140280
[TBL] [Abstract][Full Text] [Related]
11. Benefits of sacubitril/valsartan use in patients with chronic heart failure after cardiac valve surgery: a single-center retrospective study.
Zheng J; Wu Q; Li Q; Tang M; He J; Qiu Z; Xie L; Chen L
J Cardiothorac Surg; 2023 Apr; 18(1):138. PubMed ID: 37041595
[TBL] [Abstract][Full Text] [Related]
12. [Effect of sacubitril/valsartan on cardiac function in heart failure rabbits with preserved ejection fraction].
Gao SY; Yao DH; Li JF; Xie QM; Jiang SC
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):887-893. PubMed ID: 31744278
[No Abstract] [Full Text] [Related]
13. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study.
Wang C; Lin Z; Miao D; Zhang H; Fu K; Zhang X; Xiao J; Hu Y; Sun Y; Wang F; Lu H; Ji X
ESC Heart Fail; 2023 Jun; 10(3):1961-1971. PubMed ID: 36991256
[TBL] [Abstract][Full Text] [Related]
14. Clinical Effect of Qili Qiangxin Capsule Combined with Sacubitril-Valsartan in Patients with Chronic Heart Failure.
Yao J; Liu D
J Healthc Eng; 2022; 2022():8598806. PubMed ID: 35368935
[TBL] [Abstract][Full Text] [Related]
15. Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study.
Chen W; Liu Y; Li Y; Dang H
ESC Heart Fail; 2021 Oct; 8(5):3783-3790. PubMed ID: 34155812
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of sacubitril/valsartan in peritoneal dialysis patients with HFpEF and its effect on residual renal function].
Ma JW; Ren LL; Huang JC; Bao SZ; Dai LL; Ying J; Bian XY
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(2):117-124. PubMed ID: 36597739
[No Abstract] [Full Text] [Related]
17. [Sacubitril/valsartan attenuates left ventricular remodeling and improve cardiac function by upregulating apelin/APJ pathway in rats with heart failure].
Liu HZ; Gao CY; Yuan F; Xu Y; Tian H; Wang SQ; Zhang PF; Shi YN; Wei JJ
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jul; 50(7):690-697. PubMed ID: 35856226
[No Abstract] [Full Text] [Related]
18. The impact of sacubitril/valsartan on outcome in patients suffering from heart failure with a concomitant diabetes mellitus.
El-Battrawy I; Demmer J; Abumayyaleh M; Crack C; Pilsinger C; Zhou X; Mügge A; Akin I; Aweimer A
ESC Heart Fail; 2023 Apr; 10(2):943-954. PubMed ID: 36479630
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Changes in Natriuretic Peptides and Reverse Cardiac Remodeling in Patients with Heart Failure Treated with Sacubitril/Valsartan Across the Left Ventricular Ejection Traction Spectrum.
Yamamoto M; Ishizu T; Sato K; Minami K; Terauchi T; Nakatsukasa T; Kawamatsu N; Machino-Ohtsuka T; Ieda M
Int Heart J; 2023 Nov; 64(6):1071-1078. PubMed ID: 37967975
[TBL] [Abstract][Full Text] [Related]
20. Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.
Guo Y; Ren M; Wang T; Wang Y; Pu T; Li X; Yu L; Wang L; Liu P; Tang L
Front Cardiovasc Med; 2022; 9():955780. PubMed ID: 36440034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
